On April 25, the Drug Controller General of India (DCGI) gave final approval to Biological E’s Corbevax COVID-19 vaccine for administration to children in the age group of 5-12 years, making it the first vaccine candidate in India to receive the regulator’s nod for inoculation in this age-group.
Biological E was the first vaccine manufacturing company in India to have received an advance payment of Rs 1,500 crore from the Centre for reserving 30 crore doses of Corbevax before it was granted emergency use authorisation (EUA) by the regulator in 2021, after the deadly second wave had hit India in May.
Today, over 3.39 crore doses of Corbevax vaccine has been administered to children in India in the age group of 12-14 years. Moneycontrol spoke to Lakshminarayana Neti, Chief Operating Officer (COO) of Biological E on new approvals, the vaccine’s efficacy against Omicron and other important issues related to Corbevax. Edited excerpts:
Corbevax has been permitted for administration in children of age group 5-12 years by DCGI. And there is huge demand for the vaccine. Please tell us about the vaccine production capacity?